The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?-Reference-Cited by-同舟云学术

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?

Published:2011-02 Issue:2 Volume:106 Page:199-212
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:

Author:

D'Haens Geert R,Panaccione Remo,Higgins Peter D R,Vermeire Severine,Gassull Miquel,Chowers Yehuda,Hanauer Stephen B,Herfarth Hans,Hommes Daan W,Kamm Michael,Löfberg Robert,Quary A,Sands Bruce,Sood A,Watermayer G,Lashner Bret,Lémann Marc,Plevy Scott,Reinisch Walter,Schreiber Stefan,Siegel Corey,Targan Stephen,Watanabe M,Feagan Brian,Sandborn William J,Colombel Jean Frédéric,Travis Simon

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Link

http://www.nature.com/articles/ajg2010392.pdf

Reference122 articles.

1. Infliximab for induction and maintenance therapy for ulcerative colitis.;Rutgeerts;N Engl J Med,2005

2. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial.;Hanauer;Lancet,2002

3. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohns disease: the CLASSIC-I trial.;Hanauer;Gastroenterology,2006

4. Adalimumab for maintenance of clinical response and remission in patients with Crohns disease: the CHARM trial.;Colombel;Gastroenterology,2007

5. PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohns disease.;Schreiber;New Engl J Med,2007

Cited by 367 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Co-administration of 1,25-dihydroxyvitamin D3 and infliximab improves colitis in mice by modulating Treg differentiation;IRAN J BASIC MED SCI;2024

2. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08

3. Absolute monocyte counts could predict disease activity and secondary loss of response of patients with Crohn’s disease treated with anti-TNF-α drug;PLOS ONE;2024-04-10

4. Attenuation of Chronic Inflammation in Intestinal Organoids with Graphene Oxide-Mediated Tumor Necrosis Factor-α_Small Interfering RNA Delivery;Langmuir;2024-02-07

5. Controversies in the management of anti-TNF therapy in patients with Crohn’s disease: a Delphi consensus;BMJ Open Gastroenterology;2024-01